State Board of Administration of Florida Retirement System Trims Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

State Board of Administration of Florida Retirement System lessened its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Rating) by 25.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 10,473 shares of the company’s stock after selling 3,530 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Stoke Therapeutics were worth $97,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Ensign Peak Advisors Inc bought a new stake in shares of Stoke Therapeutics during the 1st quarter valued at about $25,000. Point72 Hong Kong Ltd bought a new stake in shares of Stoke Therapeutics during the 1st quarter valued at about $27,000. UBS Group AG bought a new stake in shares of Stoke Therapeutics during the 3rd quarter valued at about $47,000. Quantbot Technologies LP boosted its position in shares of Stoke Therapeutics by 207.1% during the 1st quarter. Quantbot Technologies LP now owns 4,300 shares of the company’s stock valued at $90,000 after acquiring an additional 2,900 shares during the last quarter. Finally, Simplex Trading LLC bought a new stake in shares of Stoke Therapeutics during the 4th quarter valued at about $98,000.

Stoke Therapeutics Stock Performance

Shares of STOK stock opened at $11.90 on Wednesday. Stoke Therapeutics, Inc. has a fifty-two week low of $6.88 and a fifty-two week high of $22.87. The stock has a 50 day moving average price of $9.32 and a two-hundred day moving average price of $9.05. The company has a market capitalization of $525.86 million, a P/E ratio of -4.82 and a beta of 0.41.

Stoke Therapeutics (NASDAQ:STOK – Get Rating) last announced its quarterly earnings data on Thursday, May 4th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.17. Stoke Therapeutics had a negative return on equity of 47.86% and a negative net margin of 679.83%. The firm had revenue of $5.15 million during the quarter, compared to the consensus estimate of $3.57 million. As a group, equities analysts predict that Stoke Therapeutics, Inc. will post -2.59 earnings per share for the current year.

Insider Buying and Selling

In other Stoke Therapeutics news, insider Barry Ticho sold 24,697 shares of the business’s stock in a transaction on Wednesday, May 3rd. The stock was sold at an average price of $10.14, for a total value of $250,427.58. Following the sale, the insider now directly owns 56,548 shares of the company’s stock, valued at $573,396.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.70% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on STOK. Canaccord Genuity Group began coverage on Stoke Therapeutics in a research report on Wednesday, April 26th. They set a “buy” rating and a $24.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, March 7th. Bank of America upgraded Stoke Therapeutics from an “underperform” rating to a “neutral” rating and boosted their target price for the stock from $9.00 to $12.00 in a research report on Monday, May 1st. Needham & Company LLC restated a “buy” rating and issued a $25.00 target price on shares of Stoke Therapeutics in a research report on Thursday, March 16th. Finally, Cantor Fitzgerald boosted their target price on Stoke Therapeutics from $20.00 to $25.00 in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $25.50.

Stoke Therapeutics Profile

(Get Rating)

Stoke Therapeutics, Inc is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.